arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

IDEXX Laboratories, Inc.

IDXX Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances
$535.38
Today
as of Sep 4, 16:50 ET
Last 30 days -6.00% Jul 28 → Sep 04
$523.97 $543.25 $562.52 $581.80 $601.08 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$522.05
High
$536.09
Low
$522.05
Volume
$405,812
Avg Vol
$556,709
Mkt Cap
$44.7B
P/E (TTM)
48.06
Beta
—
52w High
$769.98
52w Low
$518.55
Div Yield
—
Shares Out
$79M

Recent Press Releases & News last 60 days · 25 items

lean bull ▲ 4 ● 21 ▼ 0
Sep 3 · 15:30 Zacks neutral
Idexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
Aug 31 · 18:00 PR Business Wire neutral
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
Aug 26 · 12:09 Barchart neutral
Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$519
$770
7% of range
Avg surprise (last 3)
+4.2%
Avg reaction (last 2)
+4.5%
50% positive
Latest IV / EM
28%
EM ±4.4% · $540 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$2.44$2.90$3.35$3.81$4.27 Actual $2.55Actual $2.67Actual $2.53Actual $2.81Actual $2.44Actual $2.80Actual $2.96Est $2.92Actual $3.63Est $3.31Actual $3.40Actual $3.47Est $3.42Actual $4.27 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$0$319M$639M$958M$1.3B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $4.27 — — — — financials
Tue May 5, 2026Mar/2026 $3.47 $3.42 +1.5% +17.2% -0.0% earnings
Tue Sep 30, 2025Sep 2025 $3.40 — — — — financials
Mon Aug 4, 2025Jun/2025 $3.63 $3.31 +9.7% — — earnings
Thu May 1, 2025Mar/2025 $2.96 $2.92 +1.4% — +9.0% earnings
Mon Sep 30, 2024Sep 2024 $2.80 — — — — financials
Sun Jun 30, 2024Jun 2024 $2.44 — — — — financials
Sun Mar 31, 2024Mar 2024 $2.81 — — — — financials
Sat Sep 30, 2023Sep 2023 $2.53 — — — — financials
Fri Jun 30, 2023Jun 2023 $2.67 — — — — financials
Fri Mar 31, 2023Mar 2023 $2.55 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1.22B$1.14B—$1.11B$1.11B$998M—$976M
Cost of revenue$437M$418M—$422M$415M$375M—$380M
Gross profit$779M$723M—$683M$695M$623M—$596M
Operating income$426M$363M—$355M$373M$317M—$304M
Net income$338M$278M—$275M$294M$243M—$233M
EPS (diluted)$4.27$3.47—$3.40$3.63$2.96—$2.80

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$197M$201M$180M$208M$165M$164M$288M$309M
Inventory$392M$382M$378M$392M$393M$396M$382M$390M
Total current assets$1.51B$1.45B$1.41B$1.48B$1.36B$1.32B$1.40B$1.43B
Total assets$3.44B$3.39B$3.35B$3.39B$3.33B$3.21B$3.29B$3.35B
Long-term debt$300M$300M$375M$375M$450M$450M$450M$525M
Total liabilities$1.83B$1.83B$1.75B$1.83B$1.87B$1.77B$1.70B$1.73B
Total equity$1.61B$1.56B$1.61B$1.56B$1.46B$1.45B$1.60B$1.62B

Implied volatility — last 90 days

25%32%40%47%55% Jun 07 — IV 37% · EM ±5.1%Jun 08 — IV 35% · EM ±4.6%Jun 09 — IV 33% · EM ±4.1%Jun 10 — IV 35% · EM ±4.2%Jun 11 — IV 32% · EM ±3.6%Jun 12 — IV 31% · EM ±3.1%Jun 15 — IV 34% · EM ±2.4%Jun 16 — IV 40% · EM ±2.4%Jun 17 — IV 52% · EM ±2.2%Jun 19 — IV 31% · EM ±6.8%Jun 22 — IV 31% · EM ±6.5%Jun 23 — IV 30% · EM ±6.0%Jun 24 — IV 32% · EM ±6.4%Jun 25 — IV 31% · EM ±6.1%Jun 26 — IV 31% · EM ±5.9%Jun 29 — IV 31% · EM ±5.5%Jun 30 — IV 28% · EM ±4.9%Jul 01 — IV 30% · EM ±5.0%Jul 02 — IV 28% · EM ±4.5%Jul 03 — IV 29% · EM ±4.5%Jul 06 — IV 32% · EM ±4.4%Jul 07 — IV 32% · EM ±4.2%Jul 08 — IV 31% · EM ±3.8%Jul 09 — IV 29% · EM ±3.4%Jul 10 — IV 25% · EM ±2.8%Jul 13 — IV 36% · EM ±3.0%Jul 14 — IV 35% · EM ±2.5%Jul 15 — IV 40% · EM ±2.4%Jul 16 — IV 50% · EM ±2.1%Jul 20 — IV 51% · EM ±12.0%Jul 21 — IV 49% · EM ±11.3%Jul 22 — IV 49% · EM ±11.3%Jul 23 — IV 49% · EM ±11.1%Jul 24 — IV 49% · EM ±10.9%Jul 27 — IV 51% · EM ±10.6%Jul 28 — IV 51% · EM ±10.4%Jul 29 — IV 51% · EM ±10.3%Jul 30 — IV 53% · EM ±10.4%Jul 31 — IV 52% · EM ±9.9%Aug 03 — IV 55% · EM ±9.8%Aug 04 — IV 40% · EM ±6.9%Aug 05 — IV 37% · EM ±6.2%Aug 06 — IV 36% · EM ±5.8%Aug 07 — IV 34% · EM ±5.3%Aug 10 — IV 35% · EM ±4.9%Aug 11 — IV 38% · EM ±5.0%Aug 12 — IV 39% · EM ±4.8%Aug 13 — IV 33% · EM ±3.9%Aug 14 — IV 33% · EM ±3.6%Aug 17 — IV 35% · EM ±2.9%Aug 18 — IV 33% · EM ±2.4%Aug 19 — IV 31% · EM ±1.8%Aug 20 — IV 40% · EM ±1.7%Aug 24 — IV 30% · EM ±6.3%Aug 25 — IV 29% · EM ±5.8%Aug 26 — IV 31% · EM ±6.2%Aug 27 — IV 28% · EM ±5.5%Aug 28 — IV 27% · EM ±5.2%Aug 31 — IV 28% · EM ±4.9%Sep 01 — IV 28% · EM ±4.9%Sep 02 — IV 28% · EM ±4.7%Sep 03 — IV 27% · EM ±4.3%Sep 04 — IV 28% · EM ±4.4%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in